Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04217694 · ClinicalTrials.gov registry record · Early Phase 1
Memantine for the Reduction of Cognitive Impairment After Radiation Therapy in Pediatric Patients With Central Nervous System Tumors
A Early Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 18
- Enrollment target
NCT04217694: Completed Early Phase 1 study, sponsored by Mayo Clinic.
NCT04217694 is a Early Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 18 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04217694, a Early Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
This early phase I trial studies the feasibility of giving memantine for the reduction of cognitive impairment after radiation therapy in pediatric patients with central nervous system tumors. Memantine may reduce the effects of radiation therapy on memory and thinking.
Interventions
- DRUG Memantine
- DRUG Memantine Hydrochloride
- BEHAVIORAL Cogstate Assessment Battery
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2020-02-17 |
| Est. Completion | 2024-08-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04217694
The ClinicalTrials.gov registry entry for NCT04217694 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Memantine is the first listed.
NCT04217694 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04217694 about?
NCT04217694 is a clinical study titled "Memantine for the Reduction of Cognitive Impairment After Radiation Therapy in Pediatric Patients With Central Nervous System Tumors". This early phase I trial studies the feasibility of giving memantine for the reduction of cognitive impairment after radiation therapy in pediatric patients with central nervous system tumors. Memantine may reduce the effects of radiation therapy on memory and thinking.
What is the current status of trial NCT04217694?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 18 participants. The study started on 2020-02-17. Estimated completion is 2024-08-12.
What interventions are being tested in trial NCT04217694?
The interventions under investigation include: Memantine (DRUG), Memantine Hydrochloride (DRUG), Cogstate Assessment Battery (BEHAVIORAL).
Who is sponsoring clinical trial NCT04217694?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.